Olmesartan/Amlodipin/Hct Viatris (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/HCT is indicated for the management of hypertension, acting on the renin‑angiotensin system, calcium channels and renal sodium handling.

• Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: adds diuretic action to control volume overload.
• Hypertension requiring combination therapy: provides synergistic blood‑pressure control when monotherapy is insufficient.

• Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Hydrochlorothiazide reduces sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The three mechanisms together produce additive antihypertensive effects.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Flushing: warm sensation and reddening of skin.
• Fatigue: general tiredness.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Renal impairment: worsening kidney function.
• Electrolyte imbalance: hyper‑ or hyponatremia, hyperkalemia.
• Hepatic dysfunction: elevated liver enzymes.
• Pancreatitis: abdominal pain with nausea.

Careful assessment and monitoring are required when using this combination.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: check serum creatinine and eGFR before and during therapy.
• Electrolyte surveillance: monitor sodium, potassium and uric acid levels.
• Hepatic impairment: use with caution in patients with liver disease.
• Pregnancy and lactation: avoid unless clearly needed; discuss risks with a healthcare professional.
• Concomitant NSAIDs: may reduce antihypertensive effect and affect renal function.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipine/HCT can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• NSAIDs: may blunt antihypertensive response and impair renal function.
• Cyclosporine: increases serum concentrations of olmesartan.
• Aliskiren: combined renin‑angiotensin blockade can cause renal dysfunction.
• Lithium: increased lithium levels and toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering effect.
• ACE inhibitors: potential for renal impairment and hyperkalemia.
• Antidiabetic agents: enhanced hypoglycaemic effect.
• Antacids (aluminum/magnesium): may affect absorption of olmesartan.
• CYP3A4 inhibitors (e.g., ketoconazole): raise amlodipine concentrations.